Published in Neurology on January 05, 2011
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (2013) 1.48
Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain (2015) 1.46
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol (2015) 1.04
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol (2012) 1.04
Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol (2011) 1.03
Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS. Neurology (2013) 1.02
MS cortical lesions on DIR: not quite what they seem? PLoS One (2013) 0.99
Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions. J Neurol Neurosurg Psychiatry (2014) 0.97
Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. J Magn Reson Imaging (2011) 0.97
Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol (2012) 0.94
Quantitative magnetic resonance imaging of cortical multiple sclerosis pathology. Mult Scler Int (2012) 0.90
Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study. J Cereb Blood Flow Metab (2012) 0.89
Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. PLoS One (2011) 0.89
Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. Eur Radiol (2012) 0.86
Patients with migraine do not have MRI-visible cortical lesions. J Neurol (2012) 0.85
Advances in understanding gray matter pathology in multiple sclerosis: are we ready to redefine disease pathogenesis? BMC Neurol (2012) 0.84
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. PLoS One (2015) 0.83
MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update. Clin Neuroradiol (2015) 0.82
Current and new directions in MRI in multiple sclerosis. Continuum (Minneap Minn) (2013) 0.82
Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis. J Neurol (2015) 0.81
The clinical impact of cerebellar grey matter pathology in multiple sclerosis. PLoS One (2014) 0.81
A Model of Population and Subject (MOPS) Intensities With Application to Multiple Sclerosis Lesion Segmentation. IEEE Trans Med Imaging (2015) 0.81
Automated patient-specific optimization of three-dimensional double-inversion recovery magnetic resonance imaging. Magn Reson Med (2015) 0.81
Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. J Neurooncol (2013) 0.81
Neuroradiological evaluation of demyelinating disease. Ther Adv Neurol Disord (2013) 0.80
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. Mult Scler Int (2013) 0.80
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis. J Magn Reson Imaging (2016) 0.79
Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics. J Neurol (2014) 0.78
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime? J Neurol Neurosurg Psychiatry (2015) 0.77
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Mult Scler Int (2013) 0.77
Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. Neuroimage Clin (2015) 0.76
Cortical Pathology in RRMS: Taking a Cue from Four Sisters. Mult Scler Int (2012) 0.76
The relevance of cortical lesions in patients with multiple sclerosis. BMC Neurol (2016) 0.76
Reliability of cortical lesion detection on double inversion recovery MRI applying the MAGNIMS-Criteria in multiple sclerosis patients within a 16-months period. PLoS One (2017) 0.75
Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis. J Neurol (2015) 0.75
Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. J Neuroinflammation (2017) 0.75
Gray and White Matter Demyelination and Remyelination Detected with Multimodal Quantitative MRI Analysis at 11.7T in a Chronic Mouse Model of Multiple Sclerosis. Front Neurosci (2016) 0.75
MS cortical lesion or not? Double inversion recovery MRI reveals some answers and uncertainties. Neurology (2011) 0.75
Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS. PLoS One (2016) 0.75
In vivo detection of connectivity between cortical and white matter lesions in early MS. Mult Scler (2016) 0.75
Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions. Electron Physician (2017) 0.75
Pharmacological MRI (phMRI) of the Human Central Nervous System. Clin Neuroradiol (2015) 0.75
7T MRI Visualization of Cortical Lesions in Adolescents and Young Adults with Pediatric-Onset Multiple Sclerosis. J Neuroimaging (2017) 0.75
Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A (2006) 19.60
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke (2001) 5.81
Reduced resting-state brain activity in the "default network" in normal aging. Cereb Cortex (2007) 5.28
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage (2004) 3.25
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci (1993) 3.16
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Cortical lesions in multiple sclerosis. Brain (1999) 2.83
Incident lacunes influence cognitive decline: the LADIS study. Neurology (2011) 2.81
A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage (2003) 2.67
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology (2009) 2.46
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Prevalence and severity of microbleeds in a memory clinic setting. Neurology (2006) 2.29
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology (2012) 2.25
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology (2009) 2.14
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet (2001) 2.13
Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology (2012) 2.13
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Detection of delayed focal MR changes in the lateral hippocampus in transient global amnesia. Neurology (2004) 2.04
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology (2010) 2.03
Regional DTI differences in multiple sclerosis patients. Neuroimage (2008) 2.03
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler (2006) 1.99
Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology (2003) 1.94
Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: a magnetic resonance imaging study. Stroke (2003) 1.93
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology (2009) 1.88
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology (2010) 1.88
Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol (1995) 1.87
Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology (1995) 1.86
Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain (2008) 1.84
CT and MRI rating of white matter lesions. Cerebrovasc Dis (2002) 1.83
Cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome. Neurology (1999) 1.81
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler (2005) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Acute severe spinal cord dysfunction in bacterial meningitis in adults: MRI findings suggest extensive myelitis. Arch Neurol (2001) 1.79
Multisensory cortical signal increases and decreases during vestibular galvanic stimulation (fMRI). J Neurophysiol (2001) 1.79
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke (2003) 1.78
Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett (2000) 1.77
White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain (1992) 1.77
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Cervical MR imaging in postural headache: MR signs and pathophysiological implications. AJNR Am J Neuroradiol (2001) 1.73
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
MR venography of multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.72
Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev (2005) 1.69
A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage (2005) 1.68
Hippocampal atrophy in Alzheimer disease: age matters. Neurology (2006) 1.66
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci (2011) 1.66
Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia (2006) 1.66
Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol (2010) 1.66
Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry (2010) 1.65
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology (2004) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology (1995) 1.63
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke (2002) 1.62
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62
Clinicotopographical correlation of corticospinal tract stroke: a color-coded diffusion tensor imaging study. Stroke (2003) 1.61
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol (2009) 1.60
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology (2010) 1.58
Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. AJNR Am J Neuroradiol (2011) 1.58
Whole-body high-field MRI shows no skeletal muscle degeneration in young patients with recessive myotonia congenita. Acta Neurol Scand (2009) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain (2001) 1.56
Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation (2001) 1.56
Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. Hippocampus (2000) 1.55
Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol (2001) 1.54